ArticleOncotarget2016

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.

Xiaoen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.